WA
SGYP

Winfield Associates’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Winfield Associates’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,250
Closed -$8K – 811
2016
Q4 		$8K Hold
1,250
– – ﹤0.01% 386
2016
Q3 		$7K Hold
1,250
– – ﹤0.01% 375
2016
Q2 		$5K Buy
+1,250
New +$4.24K ﹤0.01% 413

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Winfield Associates's SGYP Position: Q1 2017 in Review

Winfield Associates sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2017, closing a stake of 1,250 shares — an estimated $8K sold.

Winfield Associates first reported a position in SGYP in Q2 2016 and held it in 3 quarters. The position peaked at $8K in Q4 2016. 164 funds tracked by Wall St. Rank hold SGYP as of Q1 2017.

  • Winfield Associates reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2017 after selling out during the quarter.
  • Winfield Associates sold 1,250 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2017, an estimated $8K.
  • Winfield Associates first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2016 and held it in 3 quarters.
  • Winfield Associates's Synergy Pharmaceuticals, Inc Common Stock position peaked at $8K in Q4 2016.
  • 164 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2017.

Based on Winfield Associates's 13F filing for Q1 2017, filed 10 May 2017.